Shopping Cart
Remove All
Your shopping cart is currently empty
RMC5127
Copy Product Info
😃Good
Catalog No. T204085Cas No. 3056146-38-1
Alias RMC-5127, RMC 5127
RMC5127 is an orally available, mutation-selective RAS G12V inhibitor exhibiting central nervous system (CNS) and brain permeability. It suppresses the RAS pathway and induces apoptosis in KRAS G12V mutant cancer cells, demonstrating antitumour activity.
RMC5127
Copy Product Info😃Good
Purity: 99.96%
Catalog No. T204085Alias RMC-5127, RMC 5127Cas No. 3056146-38-1
RMC5127 is an orally available, mutation-selective RAS G12V inhibitor exhibiting central nervous system (CNS) and brain permeability. It suppresses the RAS pathway and induces apoptosis in KRAS G12V mutant cancer cells, demonstrating antitumour activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $396 | - | In Stock | |
| 5 mg | $993 | - | In Stock | |
| 10 mg | $1,590 | - | In Stock | |
| 25 mg | $3,360 | - | In Stock | |
| 50 mg | $4,970 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.96%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | RMC5127 is an orally available, mutation-selective RAS G12V inhibitor exhibiting central nervous system (CNS) and brain permeability. It suppresses the RAS pathway and induces apoptosis in KRAS G12V mutant cancer cells, demonstrating antitumour activity. |
| In vitro | In a panel of human cancer cell lines harboring the KRASG12V mutation, RMC5127 significantly suppressed RAS pathway activity, inhibited cell proliferation, and induced cell apoptosis; however, in a panel of K/N/HRAS wild-type cancer cell lines, this drug only exerted a submaximal inhibitory effect [1]. |
| In vivo | Following repeated oral administration of RMC5127 to subcutaneous cell line-derived xenograft (CDX) models and patient-derived xenograft (PDX) models of non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC) harboring the KRASG12V mutation, significant and durable antitumor activity was observed. In the whole brain tissues of naïve mice (tumor-free mice), dose-dependent exposure of RMC5127 was detected, indicating that this compound possesses blood-brain barrier penetration ability [1]. |
| Synonyms | RMC-5127, RMC 5127 |
| Molecular Weight | 1062.32 |
| Formula | C57H75N9O9S |
| Cas No. | 3056146-38-1 |
| Smiles | C[C@H](OC)C(N=C1)=[C@@]([C@@]2=C(CC(C)(C)COC([C@H]3NN(C([C@@H](NC([C@H]4OC[C@@H]4C)=O)[C@H]5N6CC7(COC7)C6)=O)C8CC3C8)=O)C9=C(C=CC(C%10=CSC5=N%10)=C9)N2CCOC%11CCOCC%11)C=C1N%12CCN(C%13CC%13)CC%12 |
| Relative Density. | no data available |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (94.13 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy RMC5127 | purchase RMC5127 | RMC5127 cost | order RMC5127 | RMC5127 chemical structure | RMC5127 in vivo | RMC5127 in vitro | RMC5127 formula | RMC5127 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.